TOPⅡ联合Ki-67和p53表达对局部晚期乳腺癌化疗敏感性的预测分析_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 李红生 ¹ , 罗丽琼 ¹ , 马永录 ¹ , 田君才 ² , 戴伟平 ²

1. ;
2. ;

Corresponding author：

李红生, Email: 745279057@qq.com

Keywords：

乳腺肿瘤; 治疗; 拓扑异构酶Ⅱ; p53基因; 增生细胞核抗原

DOI：

10.7507/1007-9424.20150026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的探讨TOPⅡ联合p53和Ki-67的表达对局部晚期乳腺癌化疗敏感性的预测价值。方法采用免疫组化方法检测90例乳腺癌患者不同分子分型的TOPⅡ、p53和Ki-67的表达状况，比较不同TOPⅡ、p53及Ki-67表达状况患者接受新辅助化疗的疗效差异。结果 Ki-67表达阳性率在HER2过表达型、Basal-like型、腺腔A型和腺腔B型之间的差异具有统计学意义（χ²=38.877，P=0.000），其中HER2过表达型和Basal-like型高于腺腔A型和腺腔B型；TOPⅡ及p53的表达表达阳性率在4种分子分型间的差异无统计学意义（χ²=7.105，P=0.069；χ²=7.105，P=0.069）。TOPⅡ和Ki-67表达阳性者的新辅助化疗疗效优于表达阴性者χ²=18.28，P=0.000；χ²=6.64，P=0.009；而p53的表达状况与新辅助化疗的敏感性无关。结论 HER2过表达型和Basal-like型乳腺癌患者对新辅助化疗敏感，疗效好；TOPⅡ表达阳性并Ki-67表达阳性可作为乳腺癌临床化疗患者敏感性生物学指标。

Citation： 李红生, 罗丽琼, 马永录, 田君才, 戴伟平. TOPⅡ联合Ki-67和p53表达对局部晚期乳腺癌化疗敏感性的预测分析. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(1): 102-105. doi: 10.7507/1007-9424.20150026 Copy

1.	Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol, 2011, 22(8):1736-1747.
2.	杨雪宁, 吴一龙.实体瘤治疗评价标准-RECIST.循证医学, 2004, 4(2):85-90.
3.	孙立婷, 郭丽英.Ki-67抗原与乳腺癌的相关性研究.中国普外基础与临床杂志, 2014, 21(5):650-653.
4.	张继运, 沙新海, 于明涛.C-erbB-2、p53、Ki-67及VEGF在乳腺癌中的表达及相关性.实用癌症杂志, 2012, 27(3):241-243.
5.	王跃华, 李建民, 李丽, 等.乳腺癌组织中拓扑异构酶Ⅱα基因的检测及临床应用.诊断病理学杂志, 2010, 17(6):416-419.
6.	Berger JM, Gamblin SJ, Harrison SC, et al.Structure and mechanism of DNA topoismeraseⅡ.Nature, 1996, 379(6562):225-232.
7.	Harris LN, Yang L, Tang C, et al.Induction of sensitiyity to Doxorubicin and Etoposide by transfection of MCF-7 breast cancer cells with heregulinβ-2.Clin Cancer Ras, 1998, 4(4):1005-1012.
8.	Durbecq V, Paesmans M, Cardose F, et al.Topoisomerase-Ⅱalpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.Mol Cancre Ther, 2004, 3(10):1207-1214.
9.	Di LA, Gancberg D, Larsimont D, et al.HER-2 amplification and topoisomerase-Ⅱalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Clin Cancer Res, 2002, 8(5):1107-1116.
10.	刘春萍, 逯翀, 田源, 等.乳腺癌Her-2与TOP2A基因表达对新辅助化疗效果的预测价值.中国普通外科杂志, 2010, 19(11):1200-1203.
11.	吴一萍, 曹晓智.CerbB-2、p53、ER和PR受体在乳腺癌组织中的表达及意义.中国肿瘤临床与康复, 2009, 16(2):105-107.
12.	刘建诚, 姜忠敏, 李新, 等.maspin和p53在乳腺癌中的表达及临床意义.中国普外基础与临床杂志, 2013, 20(5):547-550.
13.	Rahmanzadeh R, Rai P, Celli JP, et al.ki-67 a molecular target for therapy in an in vitro three-dimensional model for o-varian cancer.Cancer Res, 2010, 70(22):9234-9242.
14.	朱学强, 任刚, 胡洪林.乳腺癌组织中VEGF、CerbB-2、p53、Ki67的表达及临床意义.西部医学, 2009, 21(3):427-429.
15.	张丽, 曾梅, 田林, 等.Cyclin D1、Ki-67及PTEN在乳腺癌中的表达及意义.现代肿瘤医学, 2013, 21(8):1772-1774.
16.	Carey LA, Dees EC, Sawyer L, et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res, 2007, 15(13):2329-2334.

1. Goldhirsch A, Wood WC, Coates AS, et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol, 2011, 22(8):1736-1747.
2. 杨雪宁, 吴一龙.实体瘤治疗评价标准-RECIST.循证医学, 2004, 4(2):85-90.
3. 孙立婷, 郭丽英.Ki-67抗原与乳腺癌的相关性研究.中国普外基础与临床杂志, 2014, 21(5):650-653.
4. 张继运, 沙新海, 于明涛.C-erbB-2、p53、Ki-67及VEGF在乳腺癌中的表达及相关性.实用癌症杂志, 2012, 27(3):241-243.
5. 王跃华, 李建民, 李丽, 等.乳腺癌组织中拓扑异构酶Ⅱα基因的检测及临床应用.诊断病理学杂志, 2010, 17(6):416-419.
6. Berger JM, Gamblin SJ, Harrison SC, et al.Structure and mechanism of DNA topoismeraseⅡ.Nature, 1996, 379(6562):225-232.
7. Harris LN, Yang L, Tang C, et al.Induction of sensitiyity to Doxorubicin and Etoposide by transfection of MCF-7 breast cancer cells with heregulinβ-2.Clin Cancer Ras, 1998, 4(4):1005-1012.
8. Durbecq V, Paesmans M, Cardose F, et al.Topoisomerase-Ⅱalpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.Mol Cancre Ther, 2004, 3(10):1207-1214.
9. Di LA, Gancberg D, Larsimont D, et al.HER-2 amplification and topoisomerase-Ⅱalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.Clin Cancer Res, 2002, 8(5):1107-1116.
10. 刘春萍, 逯翀, 田源, 等.乳腺癌Her-2与TOP2A基因表达对新辅助化疗效果的预测价值.中国普通外科杂志, 2010, 19(11):1200-1203.
11. 吴一萍, 曹晓智.CerbB-2、p53、ER和PR受体在乳腺癌组织中的表达及意义.中国肿瘤临床与康复, 2009, 16(2):105-107.
12. 刘建诚, 姜忠敏, 李新, 等.maspin和p53在乳腺癌中的表达及临床意义.中国普外基础与临床杂志, 2013, 20(5):547-550.
13. Rahmanzadeh R, Rai P, Celli JP, et al.ki-67 a molecular target for therapy in an in vitro three-dimensional model for o-varian cancer.Cancer Res, 2010, 70(22):9234-9242.
14. 朱学强, 任刚, 胡洪林.乳腺癌组织中VEGF、CerbB-2、p53、Ki67的表达及临床意义.西部医学, 2009, 21(3):427-429.
15. 张丽, 曾梅, 田林, 等.Cyclin D1、Ki-67及PTEN在乳腺癌中的表达及意义.现代肿瘤医学, 2013, 21(8):1772-1774.
16. Carey LA, Dees EC, Sawyer L, et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res, 2007, 15(13):2329-2334.

Previous Article
急性胰腺炎的综合治疗
Next Article
射频消融行保脾手术治疗体会（附24例报道）

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

TOPⅡ联合Ki-67和p53表达对局部晚期乳腺癌化疗敏感性的预测分析

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content